Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)

[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…